T cells require TRAIL for optimal graft-versus-tumor activity. - Wikidata - awgldk - TriplyDB

T cells require TRAIL for optimal graft-versus-tumor activity.

T cells require TRAIL for optimal graft-versus-tumor activity.

http://www.wikidata.org/entity/Q34158517

about

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro The biology of graft-versus-host disease: experimental systems instructing clinical practice.Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.Perforin: more than just a pore-forming protein.A cytokine-mediated link between innate immunity, inflammation, and cancer.Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells HDAC inhibition and graft versus host disease Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.TRAIL and apoptosis induction by TNF-family death receptors.Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.Pathophysiology of acute graft-versus-host disease: recent advances.TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.The TRAIL to targeted therapy of breast cancer.The role of death receptor ligands in shaping tumor microenvironment.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.Emerging apoptosis agonists for bladder cancer.GVHD prevention: an ounce is better than a pound.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Real-time detection of cellular death receptor-4 activation by fluorescence resonance energy transfer.BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.Blazing a new TRAIL in hematopoietic cell transplantation

P2860

Q33559627-0ADE1CBC-F22A-4CD8-B7B2-CF355BA651FE Q33802751-6D251708-22A7-43A6-A031-22660EBB8DBE Q33917175-D512A356-5C0F-4A61-A5BC-9A9ED58F7969 Q33991741-2591B5E6-A960-49AD-9F5E-D15A048DE56F Q34078681-F205FF17-A884-404E-ACCE-BF34829DFAA7 Q34139621-2D4E3C8B-08D1-42DC-8C17-0A2424321CE0 Q34616180-2AF835F7-8B4F-4E1E-AA4D-948553DEF09D Q34625152-F0C2269A-B490-492F-939F-0648159E06C5 Q35010607-6CFD6893-E172-4933-993F-E2BF54D47049 Q35016985-22C23D44-61EA-4206-8BAB-B968DA3DD393 Q35209364-FD481159-F0B8-436D-8938-33D2F11F24A1 Q35591708-0D297F9F-8691-4877-A0CF-84FDA1628E4B Q35849455-CF897A5B-3E44-46D5-96E2-3E348C882162 Q36156559-1D22CDC3-0F0C-405F-A017-BD59ACE57329 Q36249542-7CAEBB57-1452-4E36-AD2F-F49536CB2927 Q36365504-5D47BF31-C061-4874-B7AF-CC682F96EBD5 Q36408216-05E08508-6A47-4399-8AD8-DC8961086A94 Q36445956-B25066A0-2121-44CA-AB91-EAC9ADA4B12D Q36511919-864B6EA9-70B2-4D86-8081-D959A26AFD13 Q36693120-3727DF42-320C-472C-9C30-5E8B5D9D3D70 Q36731174-B825F28F-B4E6-4347-BD52-A831A42E6A9E Q36756712-D8D0943D-3291-4C11-865C-79CC0C960445 Q36861714-C3AA18B8-2578-4AB5-80D9-B7DEE4DA1F67 Q36891101-276B19ED-1775-4CAB-BED2-A7F9ECE6D2F0 Q36986447-7DFC0034-C588-4DB4-8172-015F72B598D6 Q36994811-EEB00635-C22A-488B-A4D4-7A3F5DFE6DE8 Q37026059-5D37F849-4D7C-4F6C-A2DE-3354E25A5919 Q37211290-61621D22-D3AC-496C-8E4C-AC248D28C4BE Q37402799-5FD48A13-8BC1-42BE-BF46-38789BA98353 Q37416883-9AF8ECA2-D4A3-4717-8938-B13C0A141ED6 Q37452305-7588F4DE-DE53-48CE-81EF-E066F9E16704 Q37601481-1034F622-E7E7-4F05-B089-E0F49714E571 Q37973859-09AA3299-E316-42EA-8944-31DA46CB8174 Q38120535-5DB56E4E-BED2-43FC-8BC1-A98C1DA8F16F Q39226276-3DF8E483-74C9-4193-B901-789A48905422 Q39337116-A7369A31-E737-48EF-8D30-2AF5A1215EBD Q39958722-FF02B04B-DB64-475C-8437-ABB7DE6D05E0 Q40350461-D8A55365-2609-4D60-BACB-AF31AF23F16D Q41131801-FC423609-A68E-45D5-8B23-72AD018FAD95 Q41285619-7A91FF1A-329C-4867-8560-BCB9CCCDF2B9

P2860

T cells require TRAIL for optimal graft-versus-tumor activity.

http://www.wikidata.org/entity/Q34158517

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

T cells require TRAIL for optimal graft-versus-tumor activity.

@ast

T cells require TRAIL for optimal graft-versus-tumor activity.

@en

T cells require TRAIL for optimal graft-versus-tumor activity.

@nl

type

label

T cells require TRAIL for optimal graft-versus-tumor activity.

@ast

T cells require TRAIL for optimal graft-versus-tumor activity.

@en

T cells require TRAIL for optimal graft-versus-tumor activity.

@nl

prefLabel

T cells require TRAIL for optimal graft-versus-tumor activity.

@ast

T cells require TRAIL for optimal graft-versus-tumor activity.

@en

T cells require TRAIL for optimal graft-versus-tumor activity.

@nl

P1433

Q34158517-C0EB234D-1EFB-4F2F-A7BF-3B4F0655DBE9

P1476

Q34158517-8C2C115E-2A29-4206-A9EB-EE0330276A82

P2093

Q34158517-39FA1F36-5DDB-4346-AC71-EE9172B662E5

Q34158517-4897531D-C865-4A50-BC1D-1ED9C5DA0DDF

Q34158517-4B730DFA-08A9-4909-AC7C-F8DB0317D201

Q34158517-57795B58-3B81-4E39-A70C-BCCC041D71BE

Q34158517-687D1757-EAA7-4FCE-B020-15BA51666A16

Q34158517-7A87347C-8CA8-4944-8BBF-19DE63669CFD

Q34158517-7CAE1A85-417B-4C62-ACA0-C0BEB3EBBE58

Q34158517-7EB5A9DE-EF4D-486E-8E5B-E969BDB5FD2A

Q34158517-968B8D5B-189D-47D6-B1AF-D306BB0A6F63

Q34158517-9B2F166C-E3B3-4158-B841-BBD097C03E93

P2860

Q34158517-18CD7CC2-925F-4905-A1A3-2296D8A7BE53

Q34158517-20498D71-357B-437B-8A2F-F79265210F63

Q34158517-270427C0-C4A8-4BC0-AA56-99F60D479F66

Q34158517-270866C8-408F-4FDB-A577-E9E761EBDE72

Q34158517-A158D413-B300-4271-AD3D-7B5D255D44B5

Q34158517-C2A3D8F9-7612-4BF5-81E2-44662EB04485

Q34158517-DFC4F1D8-2555-4A8C-8DB3-7B39F7791B00

Q34158517-E8E968C9-9214-4113-8BB3-49045A869050

Q34158517-ECDA7E6F-258B-44ED-95F0-1BF3F4910E4D

Q34158517-F52E7621-D96B-4881-A28F-7588F983ECC8

P2888

Q34158517-AB7A1A04-F925-4743-9CE4-962FE16CD61F

P304

Q34158517-DFE81A52-DFB9-442C-9CE8-B0F405FC1054

P31

Q34158517-97D0714B-E30F-4C79-979A-AE47413D3271

P356

Q34158517-A405E06D-78A4-4799-AAB3-F56B96023190

P407

Q34158517-2CD5B743-EEEF-4FF8-82B4-B153C5560D9C

P433

Q34158517-20EE860A-F33A-4581-BA59-CC65F805F59E

P478

Q34158517-ABC33141-6BB1-40DE-B2E5-B8CAA97F2A3B

P50

Q34158517-E9BC766E-D880-4EEC-BFDD-6059C27732C4

P577

Q34158517-0974235E-6207-4DEC-AC67-F82C27B0C5F1

P698

Q34158517-04DD0871-8535-4009-87EF-A4808FF1E757

P356

P1433

Nature Medicine

P1476

T cells require TRAIL for optimal graft-versus-tumor activity.

@en

P2093

Andrew S Greenberg

http://www.w3.org/2001/XMLSchema#string

Barry J Kappel

http://www.w3.org/2001/XMLSchema#string

Cornelius Schmaltz

http://www.w3.org/2001/XMLSchema#string

George F Murphy

http://www.w3.org/2001/XMLSchema#string

Henning Walczak

http://www.w3.org/2001/XMLSchema#string

Jacques J Peschon

http://www.w3.org/2001/XMLSchema#string

James M Crawford

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Eng

http://www.w3.org/2001/XMLSchema#string

Jennifer Ongchin

http://www.w3.org/2001/XMLSchema#string

Jimmy A Rotolo

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of a new member of the TNF family that induces apoptosis

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Haematopoietic cell transplantation as immunotherapy.

Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease.

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.

P2888

P304

1433-1437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1202-797

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12426560

http://www.w3.org/2001/XMLSchema#string